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DOI: http://dx.doi.org/10.1016/j.hemonc.2014.09.004BACKGROUND AND OBJECTIVES: Features and characteristics of uveal melanoma are well described in
adults, but little is known about the presentation of uveal melanoma in infancy.
DESIGN: Systematic literature review.
METHODS: A review of published, peer-reviewed literature reporting on uveal melanoma presenting during the
first two years of life. Outcome measures included demographics, clinical features, histopathological findings,
extent of the disease, therapeutic interventions, management outcomes, association with skin lesions or
systemic diseases, and survival data.
RESULTS: This review revealed 13 reported cases (seven boys and six girls) of uveal melanoma diagnosed
within the first two years of life. The median age at diagnosis was seven months. Orbital mass and proptosis
were the most common presentations (38%); only one tumor (8%) was melanotic, and pathologically 10 tumors
(77%) had epithelioid component. Associated pigmented skin lesions (cutaneous disease) were seen in six cases
(46%). All affected eyes were surgically removed; three patients received chemotherapy, and one received
radiotherapy. At a median follow-up of 25 months, two patients (15%) had metastasis, and one of them (8%)
was dead at six months’ follow-up with liver and multi-organ metastasis.
CONCLUSIONS: Uveal melanoma can present within the first two years of life. In very rare cases, it can present as
an intraocular tumor that simulates retinoblastoma, but it can also present as an orbital tumor. It has a tendency to
affect patients with cutaneous diseases like familial atypical mole, melanoma syndrome, and dysplastic nevus
syndrome. Despite this, uveal melanoma in this group has a more favorable prognosis than adult melanoma.
KEYWORDS: Choroid; Ciliary body; Iris; Melanoma; TumorUveal melanoma, the most common primaryintraocular malignant tumor in adults, is veryrare in childhood.1,2 In a series of 8000
patients with uveal melanoma; 0.12% were diagnosed
at age 10 years or younger, and no patient in that ser-
ies was two years old or younger.3
The literature contains a large body of data regard-
ing the clinical features, management, outcome, and
prognostic factors of uveal melanoma in adults,
including histopathologic features and cytogenetic fac-
tors.4,5 However, little information is available on the
speciﬁc clinical characteristics, pathologic features,
survival, and late effects of uveal melanoma diagnosedin the ﬁrst few months of life. This information may
serve to advance treatment, educate healthcare provid-
ers, and improve monitoring and rehabilitation efforts
for this speciﬁc entity of patients. We therefore pres-
ent a literary review of the reported cases of uveal
melanoma diagnosed in the ﬁrst 24 months of life.PATIENTS AND METHODS
A search for published, peer-reviewed literature
reporting on uveal melanoma diagnosed during the
ﬁrst two years of life by MEDLINE search with key
words ‘‘uveal melanoma, choroid melanoma, ciliary1
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body melanoma, iris melanoma, and uveal tumors’’
was conducted up to March 2014. We also examined
reference lists of the reports. We analyzed in detail all
case series and case reports describing uveal melanoma
diagnosed in children aged two years or younger. We
excluded cases with any diagnosis other than mela-
noma, and reports in languages other than English
for which translation was not available.
Outcome measures included: demographics,
clinical features, radiologic features, histopathologic
ﬁndings, extent of the disease, therapeutic
interventions, and management outcomes, as well
as association with skin lesions or systemic diseases,
and survival data.RESULTS
Our review of Medline literature before March 2014
identiﬁed 13 cases of uveal melanoma diagnosed
before 24 months of age between 1966 and 2013
(Table 1).
Patients and clinical characteristics
There were seven males (54%) and six females (46%).
The affected eye was known in nine cases: in the right
eye in four cases (44%), and in the left eye in ﬁve cases
(56%). The median age at time of diagnosis was seven
months (range: 0–19 months) (Table 1).Table 1. Review of the literature: published case reports of uveal
melanoma diagnosed within the first two years of life, and their
demographics.
Author Year Country Age Sex
[1] Greer6 1966 Australia Birth Male
[2] Scheffer7 1972 Utrecht 8 months Female
[3] Fledelus8 1975 Denmark 11 months Male
[4] Jensen9 1987 NA 3 months Male
[5] Broadway10 1991 UK Birth Female
[6] Posnick11 1993 USA Birth Female
[7] Joo12 1993 NA 10 months Female
[8] Pallazzi13 2005 Brazil Birth Male
[9] Thiagarajan14 2011 India Birth Female
[10] Rai15 2011 NA 7 months Male
[11] Grabowska16 2011 Spain 19 months Male
[12] Kumar17 2011 Nepal 18 months Male
[13] Nawaiseh18 2013 Jordan 16 months Female
NA: Data not available.The presentation was variable between reported
cases. Five patients (38%) presented with orbital mass
(of variable sizes and extensions) and proptosis; two
patients (15%) presented with glaucoma; two patients
(15%) presented with facial mass; one patient (8%)
presented with leukocoria; and one patient (8%)
presented with strabismus. In two patients the
presentation was not mentioned.
In ﬁve cases (38%), the tumor was from the cho-
roid; in one case (8%) it was from the ciliary body;
in one case (8%) it was mixed choroid and ciliary
body; and in one case (8%) it was mixed iris and
ciliary body. The tumor was not mentioned in the
remaining ﬁve reports (Table 2).
Of the 13 cases, four (31%) had no extra uveal
tumor extension; one (8%) had scleral invasion; two
(15%) had extrascleral extension; three (23%) had
orbital invasion (including extraocular muscles and
orbital fat); and one case (8%) had maxillary as well
as zygomatic bone invasion (Table 2).
Regarding tumor features, 10 patients (77%) had
melanotic tumor; one (8%) had amelanotic tumor;
while tumor features were not known in two
patients (15%). Pathologically; seven cases (54%) were
mixed-cell-type malignant melanoma; three cases
(23%) were epithelioid type; one case (8%) was
spindle cell type; and the pathology was not known
in two cases. Chromosome 13 loss was reported in
one case (8%) only.
Associated pigmented skin lesions were seen in six
cases (46%), as follows: Familial atypical multiple
mole melanoma (FAMMM) syndrome in four cases
(31%); dysplastic nevus syndrome in one case (8%);
and cafe au lait spots in one case (8%). Tumor
characteristics are summarized in Table 2.
Not one of the patients in this review had a family
history of melanomas or other malignancies.
Treatment and survival
The eyes of all reported cases of uveal melanoma
diagnosed before the age of two years were surgically
removed; 11 eyes (85%) by enucleation, and two eyes
(15%) by exenteration. Systemic chemotherapy was
given in two (15%) cases as adjuvant therapy
after enucleation. In one case (8%), neoadjuvant
chemotherapy was given, but since no tumor response
was seen, exenteration was done.
One eye (8%) received external beam radiation
therapy after exenteration (Table 2).
At a median follow-up of 25 months (range
6–120 months), two cases (15%) were reported to have
metastasis. One patient (8%) who had chromosome 3
losses, and had trans-scleral invasion of epithelioid-typeHematol Oncol Stem Cell Ther 8(1) Quarter 2015
Table 2. Clinical and pathological features, management and outcome of uveal melanomas diagnosed within the first two years.
Author Greer6 1966 Scheffer7
1972
Fledelus8
1975
Jensen9 1987 Broadway10
1991
Posnick11
1993
Joo12 1993 Palazzi13 2005 Rai 15 2011 Grabowska16
2011
Thiagarajan14
2011
Kumar17
2011
Nawaiseh18
2013
Location Ciliary
body + iris
Uveal Choroid Choroid Anterior Uveal Uveal Choroid Choroid + Ciliary
body
Uveal Choroid Uveal Ciliary body Choroid
Affected eye Left Left NA NA Left Left NA Right NA Right Right Left Right
Extension Intraocular Intraocular Intraocular Intraocular Extraocular
muscles and
fat
Maxillary and
zygomatic
bones
Intraocular Sclera, optic
nerve, extraocular
muscles
Sclera Sclera Filling orbit up
to orbital apex
Intraocular Extrascleral
Type Melanotic Melanotic Melanotic Melanotic Melanotic NA Melanotic Melanotic Melanotic NA Melanotic Melanotic Amelanotic
Pathology Mixed cell NA Mixed cell Mixed cell Epithelioid NA Spindle cell Mixed cell Mixed cell Epithelioid Epithelioid Mixed Mixed
Systemic
association
Multiple
melanocytic
nevus
None None Dysplastic
nevus
syndrome
Multiple
melanocytic
nevi
None Caf au lait
spots
Multiple
melanocytic nevi
Multiple
pigmented
skin
lesions
FAMMM
None None None None
Treatment Enucleation
No CTX
Follow up
with
imaging??
Enucleation
No CTX
Enucleation
No CTX
Enucleation
followed by
CTX
Extensive
exenteration
and CTX
Enucleation
No CTX
Enucleation
followed by CTX
Enucleation
No CTX
Enucleation
No CTX
Exenteration
followed by XRT
Enucleation
No CTX
Enucleation
No CTX
Metastasis No NA NA No Liver No NA No NA Liver
Multiple
No No No
Genetics No No No No No No NA No NA Chromosome 3
loss
No No No
Last follow up 2 years NA NA 25 months 34 months 2 years NA 10 years NA 6 months NA 34 months 3 years
Outcome Alive NA NA Alive Alive Alive NA Alive NA Dead Alive Alive Alive
NA: Data not available.
CTX: Chemotherapy, XRT: Radiotherapy.
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tumor died with orbital recurrence and multiple
metastasis six months after enucleation, and
one patient (8%) who had extraocular invasion by
epithelioid type tumor had liver metastasis at his last
follow-up 34 months after enucleation and adjuvant
chemotherapy (Table 2).DISCUSSION
In a series of 8000 patients with uveal melanoma,
0.12% of patients were diagnosed between two and
10 years of age, while no patient in that series was
two years or younger.3 In our review of the literature,
only 10 patients were diagnosed with uveal melanoma
within the ﬁrst 24 months of life.
Familial atypical mole and melanoma syndrome
(FAM-M), previously described as B K mole syn-
drome,19 dysplastic nevus syndrome,20 and familial
atypical multiple mole-melanoma syndrome (FAM-
MM),21 are characterized by a hereditary predisposi-
tion to cutaneous melanoma.22 Singh et al.23 tried to
study the possible correlation between these cutane-
ous diseases and uveal melanoma by running a retro-
spective review of 4600 consecutive patients with
diagnosis of primary uveal melanoma. They found
eight patients (0.2%) who had uveal melanoma and
biopsy-proven FAM-M syndrome at the same time.23
In addition, they found that in patients with FAM-M
syndrome, the uveal melanoma occurred at a relatively
young age (mean 40 years).23 Of the total 13 cases of
uveal melanoma diagnosed in the ﬁrst 24 months of
life in our review, we found ﬁve cases (38%) of con-
genital choroidal melanoma, four of them associated
with systemic features of FAMMM, or dysplastic
nevus syndrome, and one more case diagnosed
with choroidal melanoma at age three months had
dysplastic nevus syndrome. Since atypical cutaneous
nevi in the FAM-M syndrome are the precursors of
cutaneous melanoma,24 and due to evidence of an
increased number of uveal nevi in patients with
FAM-M syndrome,25 and in addition to the reported
case of uveal nevi that showed transformation to uveal
melanoma in a patient with iris melanoma,26 we
expect that the ﬁve cases (38%) in our review who
had associated FAMMM or dysplastic nevus syn-
drome evolved from precursor lesions in the uveal
tissues.
The survival time observed for most uveal mela-
noma that extended outside the eye in adults was brief,
with death occurring within months or, exceptionally,
a few years.27 In younger patients in this review, sevenhad scleral, extrascleral, or orbital invasion and only
two (28%) had metastasis. Two patients with extraoc-
ular disease and without metastasis had received che-
motherapy, and one had received radiation therapy.
It is possible that ocular melanomas in children may
have a more favorable response to chemotherapy than
do those in adults, but given the small sample size, it
becomes impossible to draw an accurate conclusion.
The cellular composition of melanoma is impor-
tant because mixed-cell-type tumors have been associ-
ated with more tumor growth and mortality than
spindle-cell-type tumors.3 Spindle-cell type may be
more commonly found in uveal melanoma in children
(46%) than in adults,27 and that partially explains why
uveal melanoma in young patients (20 years or less)
was associated with a lower rate of metastasis than
in mid-adults and older adults.28,29 In contrast, 77%
of cases in this review were of mixed-cell-type tumors
or of epithelioid-cell-type, and despite that, metastasis
was seen only in 1% of cases. Of more interest, seven
cases (54%) in our review had extraocular tumor inva-
sion, and only two cases (15%) had metastasis. The
unexpected low rate of metastasis with these poor
prognostic pathologic and clinical features may be
due to the short follow-up time for the cases in this
review, or to different behavior between uveal mela-
noma presenting at a very young age and melanoma
in adults. Only one case in this review had genetic
analysis which showed monosomy 3: the patient
who had metastasis and who subsequently died.
Therefore, genetics in pediatric uveal melanoma may
have a more important prognostication role than clin-
ical and pathologic features. This is, however, a
premature conclusion because of the small sample size
and short follow-up.
The differential diagnosis of pediatric uveal mela-
noma includes medulloepithelioma, melanocytoma,
neuroepithelial cysts, hemangiomas and hematomas,
and acquired inﬂammatory masses. Even uveal mela-
noma in children is very rare, and should be consid-
ered in the differential diagnosis of intra ocular
mass in children, mainly when associated with predis-
posing factors such as neuroﬁbromatosis type 1, ocu-
lar or oculodermal melanocytosis, and dysplastic
nevus syndrome.
In conclusion, this review illustrates that uveal
melanoma can present within the ﬁrst 24 months of
life in very rare cases. It can present as intraocular
tumor that simulates retinoblastoma, but it can also
present as orbital tumor. It has a tendency to affect
patients with cutaneous diseases like familial atypicalHematol Oncol Stem Cell Ther 8(1) Quarter 2015
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mole and melanoma syndrome and dysplastic nevus
syndrome. Despite these facts, uveal melanoma in this
patient group has a more favorable prognosis than
adult melanoma.Hematol Oncol Stem Cell Ther 8(1) First Quarter 2015CONFLICT OF INTEREST STATEMENT
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